Molecular markers in the diagnosis of prostate cancer

被引：16
作者：
van der Poel, H. G. [1 ]
机构：
[1] Netherlands Canc Inst, Dept Urol, NL-1066 CX Amsterdam, Netherlands
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2007年 / 61卷 / 02期
关键词：
prostate cancer; molecular markers; hormone refractory disease; surgery; radiotherapy;
D O I：
10.1016/j.critrevonc.2006.07.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The genetic alterations leading to prostate cancer are gradually being discovered. A wide variety of genes have been associated with prostate cancer development as well as tumor progression. Knowledge of gene polymorphisms associated with disease aid in the understanding of important pathways involved in this process and may result in the near future in clinical applications. Urinary molecular markers will soon be available to aid in the decision of repeat prostate biopsies. Recent findings suggest the importance of androgen signaling in disease development and progression. The further understanding of interaction of inflammation, diet, and genetic predisposition will improve risk stratification in the near future. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：104 / 139
页数：36
相关论文
共 537 条
[91]   Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer [J].
Davies, B ;
Chen, J ;
Modugno, F ;
Weissfeld, J ;
Landsittel, D ;
Dhir, R ;
Nelson, J ;
Getzenberg, RH .
JOURNAL OF UROLOGY, 2005, 174 (05) :1767-1770
[92]   Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells [J].
Davis, JN ;
McCabe, MT ;
Hayward, SW ;
Park, JM ;
Day, ML .
CANCER RESEARCH, 2005, 65 (09) :3633-3642
[93]  
de la Taille A, 2003, CLIN CANCER RES, V9, P1801
[94]   E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens [J].
De Marzo, AM ;
Knudsen, B ;
Chan-Tack, K ;
Epstein, JI .
UROLOGY, 1999, 53 (04) :707-713
[95]  
Debes JD, 2002, CANCER RES, V62, P5632
[96]   Delineation of prognostic biomarkers in prostate cancer [J].
Dhanasekaran, SM ;
Barrette, TR ;
Ghosh, D ;
Shah, R ;
Varambally, S ;
Kurachi, K ;
Pienta, KJ ;
Rubin, MA ;
Chinnaiyan, AM .
NATURE, 2001, 412 (6849) :822-826
[97]   Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse [J].
Di Cristofano, A ;
De Acetis, M ;
Koff, A ;
Cordon-Cardo, C ;
Pandolfi, PP .
NATURE GENETICS, 2001, 27 (02) :222-224
[98]   Expression of proto-oncogene c-kit in high risk prostate cancer [J].
Di Lorenzo, G ;
Autorino, R ;
D'Armiento, FP ;
Mignogna, C ;
De Laurentiis, M ;
De Sio, M ;
D'Armiento, M ;
Damiano, R ;
Vecchio, G ;
De Placido, S .
EJSO, 2004, 30 (09) :987-992
[99]  
Di Lorenzo G, 2002, CLIN CANCER RES, V8, P3438
[100]   Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease [J].
Di Lorenzo, G ;
De Placido, S ;
Autorino, R ;
De Laurentiis, M ;
Mignogna, C ;
D'Armiento, M ;
Tortora, G ;
De Rosa, G ;
D'Armiento, M ;
De Sio, M ;
Bianco, AR ;
D'Armiento, FP .
PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (01) :54-59
567891011121314